CassandraBio
Pipeline dossier

NIH & clinical-trial pipeline signals for ELI LILLY & Co (LLY)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for LLY, mapped to public ticker LLY (CIK 0000059478). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →
Trial → FilingLLY35% conf

ELI LILLY & Co (LLY) — PHASE1 protocol updated 5 days ago

Upstream (observed)
Clinical trial status (PHASE1) — A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)
trial ↗filings ↗
Trial → FilingLLY35% conf

ELI LILLY & Co (LLY) — PHASE3 protocol updated 6 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)
trial ↗filings ↗
Trial → FilingLLY35% conf

ELI LILLY & Co (LLY) — PHASE1 protocol updated 12 days ago

Upstream (observed)
Clinical trial status (PHASE1) — A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)
Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)
trial ↗filings ↗

Recent SEC 8-K filings

JSON API for this entity →